EMC8: A Promising Drug Target and Biomarker for Multiple Chronic Diseases

Target Name: EMC8

NCBI ID: G10328

EMC8

EMC8: A Promising Drug Target and Biomarker for Multiple Chronic Diseases

Introduction

EMC8, also known as C16orf4, is a non-coding RNA molecule that has been identified by researchers as a potential drug target and biomarker for various chronic diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and subcellular localization in the The cell has piqued the interest of researchers, who are investigating its functions and potential uses in drug development.

EMC8's Localization and Functions

EMC8 is a long non-coding RNA molecule that has been observed to be expressed in various tissues and cells throughout the body. Its localization to specific cellular compartments, such as the nucleus and the endoplasmic reticulum, suggests that it plays an important role in the regulation of gene expression and cell function.

One of the most significant features of EMC8 is its subcellular localization. Unlike many other non-coding RNAs, EMC8 is specifically expressed in the nucleus, which is known as the central organ of the cell responsible for the expression and storage of genetic information. This localization suggests that EMC8 plays a crucial role in the regulation of gene expression and DNA replication, which are critical processes that maintain cellular identity and function.

EMC8's Interaction with DNA

EMC8 has been shown to interact with the double helix structure of DNA. This interaction is of particular interest because it suggests that EMC8 may play a role in the regulation of gene expression and DNA replication, which are critical processes that are tightly linked in the control of gene identity and function.

One of the most significant functions of EMC8 is its role in the regulation of gene expression. This function is critical for the development and maintenance of cellular identity and for the regulation of cellular processes that are essential for life. For example, EMC8 has been shown to play a role in the regulation of cell cycle progression, which is the process by which cells grow, divide, and replicate their genetic material.

EMC8's Role in Neurodegenerative Diseases

EMC8's involvement in the regulation of gene expression and DNA replication has also led to its potential as a drug target and biomarker for neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of neural cells and the development of neurofibrillary tangles and other hallmark pathological hallmarks.

EMC8's potential as a drug target and biomarker for neurodegenerative diseases is based on its ability to interact with the double helix structure of DNA and its role in the regulation of gene expression. By targeting EMC8, researchers may be able to disrupt the regulation of gene expression. and DNA replication, which could lead to the progressive loss of neural cells and the development of neurofibrillary tangles that are characteristic of neurodegenerative diseases.

EMC8's Potential as a Biomarker

EMC8's localization to the nucleus and its interaction with the double helix structure of DNA also make it an attractive biomarker for various diseases, including cancer. The regulation of gene expression and DNA replication are critical processes that are closely monitored by the immune system, and changes in these processes can be an indication of the presence of cancer cells.

EMC8 has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that EMC8 may be a useful biomarker for the detection and diagnosis of these diseases. In addition, the regulation of gene expression and DNA replication by EMC8 may also be disrupted by cancer treatments, which could provide a therapeutic target for cancer therapies.

EMC8's Potential Therapeutic Applications

EMC8's unique structure and cellular sub-localization, as well as its interaction with the double

Protein Name: ER Membrane Protein Complex Subunit 8

Functions: Part of the endoplasmic reticulum membrane protein complex (EMC) that enables the energy-independent insertion into endoplasmic reticulum membranes of newly synthesized membrane proteins (PubMed:30415835, PubMed:29809151, PubMed:29242231, PubMed:32459176, PubMed:32439656). Preferentially accommodates proteins with transmembrane domains that are weakly hydrophobic or contain destabilizing features such as charged and aromatic residues (PubMed:30415835, PubMed:29809151, PubMed:29242231). Involved in the cotranslational insertion of multi-pass membrane proteins in which stop-transfer membrane-anchor sequences become ER membrane spanning helices (PubMed:30415835, PubMed:29809151). It is also required for the post-translational insertion of tail-anchored/TA proteins in endoplasmic reticulum membranes (PubMed:29809151, PubMed:29242231). By mediating the proper cotranslational insertion of N-terminal transmembrane domains in an N-exo topology, with translocated N-terminus in the lumen of the ER, controls the topology of multi-pass membrane proteins like the G protein-coupled receptors (PubMed:30415835). By regulating the insertion of various proteins in membranes, it is indirectly involved in many cellular processes (Probable)

The "EMC8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EMC8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets